Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.Lancet Oncol 2021 Sep 30;[EPub Ahead of Print], F Saad, E Efstathiou, G Attard, TW Flaig, F Franke, OB Goodman, S Oudard, T Steuber, H Suzuki, D Wu, K Yeruva, P De Porre, S Brookman-May, S Li, J Li, S Thomas, KB Bevans, SD Mundle, SA McCarthy, DE Rathkopf
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.